H.C. Wainwright Initiates Coverage on Aerpio Pharmaceuticals Inc (ARPO). What May be Next?

May 24, 2018 - By wolcottdaily

Why Has H.C. Wainwright Given Aerpio Pharmaceuticals Inc (ARPO) a $10.0000 Price Target

EU: Aerpio Pharmaceuticals Inc (ARPO) coverage was started with a key ‘Buy’ rating as well as a $10.0000 target price per share at H.C. Wainwright. The target price by H.C. Wainwright would suggest upside of 146.91 % from the previous close.

The stock decreased 1.22% or $0.05 during the last trading session, reaching $4.05. About 400 shares traded. Aerpio Pharmaceuticals, Inc. (ARPO) has 0.00% since May 24, 2017 and is . It has underperformed by 11.55% the S&P500.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company has market cap of $109.95 million. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema. It currently has negative earnings. It also develops ARP-1536, a humanized monoclonal antibody that is in late stage preclinical development for the treatment of wet age-related macular degeneration; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a Phase 1a clinical trial for the treatment of inflammatory bowel disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.